Drugs / Fluzoparil
Fluzoparil
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04933175 | Jun 2021 → Jun 2022 | small cell lung carcinoma | Liu Zhenhua | Unknown | No outcome recorded |
| Phase 2 | NCT04552977 | Sep 2020 → Aug 2021 | glioblastoma | Shandong Cancer Hospital and Institute | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluzoparil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04933175 ↗ |
| Action | Inhibit | “a PARP1 inhibitor” NCT04552977 ↗ |
| Target | PARP1 | “a PARP1 inhibitor” NCT04552977 ↗ |